Cover Image

Vaxeal Holding SA的產品平台分析

Vaxeal Holding SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256041
出版日期 內容資訊 英文 18 Pages
Back to Top
Vaxeal Holding SA的產品平台分析 Vaxeal Holding SA - Product Pipeline Review - 2015
出版日期: 2015年12月30日 內容資訊: 英文 18 Pages



Vaxeal Holding SA是總公司設立於瑞士的製藥企業,開發針對癌症及傳染症的併用免疫調節藥之治療苗疫。

本報告提供Vaxeal Holding SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。


Vaxeal Holding SA的基本資料

  • Vaxeal Holding SA概要
  • 主要資訊
  • 企業資料

Vaxeal Holding SA:R&D概要

  • 主要的治療範圍

Vaxeal Holding SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Vaxeal Holding SA:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Vaxeal Holding SA:藥物簡介

  • MDX-1 Vaccine
  • SVX-1 Vaccine
  • Vaccine For Hepatitis C
  • Cancer Combination Vaccine
  • CBX-1 Vaccine

Vaxeal Holding SA:開發平台分析

  • 標的別
  • 各分子類型

Vaxeal Holding SA:開發暫停中的計劃

Vaxeal Holding SA:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司



Product Code: GMDHC07936CDB


Global Markets Direct's, 'Vaxeal Holding SA - Product Pipeline Review - 2015', provides an overview of the Vaxeal Holding SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vaxeal Holding SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • The report provides brief overview of Vaxeal Holding SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vaxeal Holding SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vaxeal Holding SA's pipeline products

Reasons to buy

  • Evaluate Vaxeal Holding SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vaxeal Holding SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vaxeal Holding SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vaxeal Holding SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vaxeal Holding SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vaxeal Holding SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vaxeal Holding SA Snapshot
    • Vaxeal Holding SA Overview
    • Key Information
    • Key Facts
  • Vaxeal Holding SA - Research and Development Overview
    • Key Therapeutic Areas
  • Vaxeal Holding SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Vaxeal Holding SA - Pipeline Products Glance
    • Vaxeal Holding SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Vaxeal Holding SA - Drug Profiles
    • CBX-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVX-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vaxeal Holding SA - Pipeline Analysis
  • Vaxeal Holding SA - Pipeline Products by Molecule Type
  • Vaxeal Holding SA - Dormant Projects
  • Vaxeal Holding SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vaxeal Holding SA, Key Information
  • Vaxeal Holding SA, Key Facts
  • Vaxeal Holding SA - Pipeline by Indication, 2015
  • Vaxeal Holding SA - Pipeline by Stage of Development, 2015
  • Vaxeal Holding SA - Monotherapy Products in Pipeline, 2015
  • Vaxeal Holding SA - Preclinical, 2015
  • Vaxeal Holding SA - Discovery, 2015
  • Vaxeal Holding SA - Pipeline by Molecule Type, 2015
  • Vaxeal Holding SA - Dormant Developmental Projects,2015
  • Vaxeal Holding SA, Subsidiaries

List of Figures

  • Vaxeal Holding SA - Pipeline by Top 10 Indication, 2015
  • Vaxeal Holding SA - Pipeline by Stage of Development, 2015
  • Vaxeal Holding SA - Monotherapy Products in Pipeline, 2015
  • Vaxeal Holding SA - Pipeline by Top 10 Molecule Type, 2015
Back to Top